Drew Moghanaki: Standard of care for stage III NSCLC remains immunotherapy after CRT
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA, shared a post on X:
“A slide discussed by Percy Lee reminds us of yet another negative phase III trial that attempted to integrate concurrent immunotherapy during CRT for stage III NSCLC.
Standard of care remains immunotherapy after CRT.”
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023